IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?
Chang, Ying-Jun1,2; Huang, Xiao-Jun1,2,3
关键词Hematopoietic Stem Cell Transplantation Relapse Donor Lymphocyte Infusion Prophylaxis Treatment
刊名BLOOD REVIEWS
2013
DOI10.1016/j.blre.2012.11.002
27期:1页:55-62
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Hematology
资助者Ministry of Health ; National Natural Science Foundation of China ; Ministry of Health ; National Natural Science Foundation of China
研究领域[WOS]Hematology
关键词[WOS]STEM-CELL TRANSPLANTATION ; BONE-MARROW-TRANSPLANTATION ; ACUTE MYELOID-LEUKEMIA ; GRAFT-VERSUS-LEUKEMIA ; CD4(+) T-CELLS ; CHRONIC MYELOGENOUS LEUKEMIA ; ACUTE LYMPHOBLASTIC-LEUKEMIA ; COLONY-STIMULATING FACTOR ; MINIMAL RESIDUAL DISEASE ; REDUCED-INTENSITY TRANSPLANTATION
英文摘要

Donor lymphocyte infusion (DLI) using unstimulated leukapheresis is one of the most effective treatment strategies for patients with hematological malignancies; its graft-versus-leukemia effects make it especially effective in chronic myeloid leukemia patients who relapsed after allogeneic stem cell transplantation (allo-HSCT). However, DLI application is limited by the development of graft-versus-host disease and aplasia, and thus cannot be routinely applied for prophylaxis. Therefore, important questions remain to be answered, such as when, and whom to DLI? Recent advances enable DLI using allografts of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells; allodepleted donor T cells; and infusions of donor-derived, ex vivo-expanded, CD8(+) cytotoxic T lymphocyte, which can decrease relapse and improve transplant outcomes. Preemptive immunotherapy of relapse was also introduced based on the determination of mixed chimerism and minimal residual disease. In this review, we summarize the latest developments in recent strategies that will affect future DLI efficacy - focusing on the disadvantages and advantages of each protocol for the treatment, preemptive therapy, and prophylaxis of relapse. (C) 2012 Elsevier Ltd. All rights reserved.

语种英语
所属项目编号30725038 ; 81230013
资助者Ministry of Health ; National Natural Science Foundation of China ; Ministry of Health ; National Natural Science Foundation of China
WOS记录号WOS:000314389700006
引用统计
被引频次:40[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52222
专题北京大学第二临床医学院
作者单位1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Peking Univ, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
3.Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Chang, Ying-Jun,Huang, Xiao-Jun. Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?[J]. BLOOD REVIEWS,2013,27(1):55-62.
APA Chang, Ying-Jun,&Huang, Xiao-Jun.(2013).Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?.BLOOD REVIEWS,27(1),55-62.
MLA Chang, Ying-Jun,et al."Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?".BLOOD REVIEWS 27.1(2013):55-62.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chang, Ying-Jun]的文章
[Huang, Xiao-Jun]的文章
百度学术
百度学术中相似的文章
[Chang, Ying-Jun]的文章
[Huang, Xiao-Jun]的文章
必应学术
必应学术中相似的文章
[Chang, Ying-Jun]的文章
[Huang, Xiao-Jun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。